Antibe Therapeutics Stock Today
| ATBPF Stock | USD 0.22 0.00 0.00% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Antibe Therapeutics is trading at 0.22 as of the 27th of November 2024. This is a No Change since the beginning of the trading day. The stock's lowest day price was 0.22. Antibe Therapeutics has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Antibe Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of December 2022 and ending today, the 27th of November 2024. Click here to learn more.
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Antibe Therapeutics Inc. The company has 52.14 M outstanding shares. More on Antibe Therapeutics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Antibe Pink Sheet Highlights
| Business Concentration | Health Care, Pharmaceuticals, Medical Devices, Healthcare (View all Sectors) |
Antibe Therapeutics [ATBPF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.59 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Antibe Therapeutics's market, we take the total number of its shares issued and multiply it by Antibe Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Antibe Therapeutics classifies itself under Pharmaceuticals sector and is part of Health Care industry. The entity has 52.14 M outstanding shares.
Antibe Therapeutics has accumulated about 50.19 M in cash with (16.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Antibe Therapeutics Probability Of Bankruptcy
Ownership AllocationAntibe Therapeutics holds a total of 52.14 Million outstanding shares. Antibe Therapeutics shows 7.79 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Antibe Ownership Details
Antibe Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Antibe Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated |
| All Next | Launch Module |
Antibe Therapeutics Corporate Management
| Philip Stern | VP Communications | Profile | |
| Ana Stegic | Director Operations | Profile | |
| LLB JD | CEO and President | Profile | |
| MEng CFA | Chief Officer | Profile | |
| MBA MSc | Founder Chair | Profile | |
| MBA DO | Chief Officer | Profile | |
| David Vaughan | Chief Devel. Officer | Profile |
Other Information on Investing in Antibe Pink Sheet
Antibe Therapeutics financial ratios help investors to determine whether Antibe Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antibe with respect to the benefits of owning Antibe Therapeutics security.